Beyond platinum treatment for NSCLC: what does the future hold?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Beyond platinum treatment for NSCLC: what does the future hold?

Published:2017-02-08 Issue:4 Volume:17 Page:293-295
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Santarpia Mariacarmela¹,Karachaliou Niki²,Rosell Rafael³⁴⁵

Affiliation:

1. Medical Oncology Unit, Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Italy

2. Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain

3. Institute of Oncology Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain

4. Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

5. Cellular and Molecular Biology Laboratory, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Barcelona, Spain

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2017.1288103

Reference21 articles.

1. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

2. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

3. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

4. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

5. Genetics and biomarkers in personalisation of lung cancer treatment

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer;American Journal of Clinical Oncology;2024-09-11

2. Bronchoalveolar Lavage Fluid Microbiota is Associated with the Diagnosis and Prognosis Evaluation of Lung Cancer;Phenomics;2024-04

3. Construction of IMMS Containing Multi-site Liposomes for Dynamic Monitoring of Blood CTC in Patients with Osimertinib-resistant Non-small-cell Lung Cancer and its Mechanism;Anti-Cancer Agents in Medicinal Chemistry;2023-04

4. Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis;Pharmacology;2022-12-05

5. Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece;Future Oncology;2022-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3